As technologies move from the lab to commercialization, changes to them need to be made to make them financially and practically appropriate for clinical settings. In Vivo spoke to two companies pioneering new types of device-activated drugs to learn about these changes and how the end products will help patients.

As technologies move from the lab to commercialization, changes to them need to be made to make them financially and practically appropriate for clinical settings. Medtech Insight spoke to two companies pioneering new types of device-activated drugs to learn about these changes and how the end products will help patients.

A steady flow of venture capital into the medical device industry continued in the first half of 2020 despite the pandemic. Medtech start-ups raised more than $1.5bn with Medtech Insight tracking over 40 financial deals of $1m-and-over.

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. The week of 9-15 July was another slow one for US FDA approvals, with no new PMAs, panel-track PMA supplements, or de novos. Informa’s Meddevicetracker reported three non-US approvals during the week.